In stage one clinical trials done at Duke University, almost half of the women with advanced breast tumors of this type (Her2) who were given Lapatinib had their disease stabilize or had their tumor shrink in the first eight weeks of the study. http://news-info.wustl.edu/news/page/normal/3564.html